Valentis (VLTS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Valentis (VLTS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (47)	5/24/2001 2:59:17 PM
From: Mike McFarland	Read Replies (2) of 81

ASGT 210 Combination Cytokine Gene Therapy Using IL-12 and IFN-a for the Treatment of Cancer 211 Gene Therapy of Melanoma with In Vivo Transfection of Tumors Using a Combination of Superantigen and Cytokine Genes A few of the authors are from Valentis. apnet.com apnet.com When I looked for Ariad ARGENT related papers, I put rapalog and the actual dimerizer numbers in there and found more abstracts that way. I have not dug around as much for Valentis related stuff--though "GeneSwitch" gave me these three: apnet.com apnet.com apnet.com --all Valentis authors here I know Ariad had a nice little run from below $4 to briefly $6 recently. Valentis has not been running up ahead of asgt--the shares did well in April but had been trickling down lately, asking 5 5/8ths now (but that might be a bit phoney, not an awful lot of shares available--I tried to buy a few at the market, and right away they were selling for $6...geeze!) It is hard to spend $6 when you could have had them for 4 1/2 a month ago. Hey, maybe Ladenburg Thalmann will pick up coverage;-) Coverage from Midnight Mike seems not to move this buggers hehheh. Okay, ambien kicking in now, Daysleeper signing off. Happy trades all.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next